{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:39:27Z","timestamp":1790127567384,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T00:00:00Z","timestamp":1295913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1038\/nrneurol.2011.1","type":"journal-article","created":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T11:52:03Z","timestamp":1295956323000},"page":"165-172","source":"Crossref","is-referenced-by-count":127,"title":["Monoclonal antibody therapy-associated neurological disorders"],"prefix":"10.1038","volume":"7","author":[{"name":"the BIOGEAS Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ramos-Casals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,25]]},"reference":[{"key":"BFnrneurol20111_CR1","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/archneur.65.9.1162","volume":"65","author":"JC Novak","year":"2008","unstructured":"Novak, J. C., Lovett-Rache, A. E. & Rache, M. K. Monoclonal antibody therapies and neurologic disorders. Arch. Neurol. 65, 1162\u20131165 (2008).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol20111_CR2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","volume":"22","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals, M., Brito-Zer\u00f3n, P., Soto, M. J., Cuadrado, M. J. & Khamashta, M. A. Autoimmune diseases induced by TNF-targeted therapies. Best Pract. Res. Clin. Rheumatol. 22, 847\u2013861 (2008).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnrneurol20111_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jns.2010.01.004","volume":"291","author":"A Faivre","year":"2010","unstructured":"Faivre, A.  et al. Acute motor and sensory axonal neuropathy and concomitant encephalopathy during tumor necrosis factor-alpha antagonist therapy. J. Neurol. Sci. 291, 103\u2013106 (2010).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol20111_CR4","unstructured":"BIOGEAS \n                    [online]\n                    \n                  , (2007)."},{"key":"BFnrneurol20111_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","volume":"9","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals, M.  et al. Autoimmune diseases induced by biological agents. A double-edged sword? Autoimmun. Rev. 9, 188\u2013193 (2010).","journal-title":"Autoimmun. Rev."},{"key":"BFnrneurol20111_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","volume":"86","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals, M.  et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86, 242\u2013251 (2007).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrneurol20111_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s11926-008-0072-z","volume":"10","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals, M., Brito-Zer\u00f3n, P., Cuadrado, M. J. & Khamashta, M. A. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr. Rheumatol. Rep. 10, 442\u2013448 (2008).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrneurol20111_CR8","doi-asserted-by":"crossref","unstructured":"Weissert, R. Progressive multifocal leukoencephalopathy. J. Neuroimmunol. doi:10.1016\/j.jneuroim.2010.09.021.","DOI":"10.1016\/j.jneuroim.2010.09.021"},{"key":"BFnrneurol20111_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/ana.22185","volume":"68","author":"KL Tyler","year":"2010","unstructured":"Tyler, K. L. Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies? Ann. Neurol. 68, 271\u2013274 (2010).","journal-title":"Ann. Neurol."},{"issue":"Suppl. 1","key":"BFnrneurol20111_CR10","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1212\/WNL.0b013e3181c97ed3","volume":"74","author":"B Bielekova","year":"2010","unstructured":"Bielekova, B. & Becker, B. L. Monoclonal antibodies in MS. Mechanisms of action. Neurology 74 (Suppl. 1), S31\u2013S40 (2010).","journal-title":"Neurology"},{"key":"BFnrneurol20111_CR11","unstructured":"The CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786\u20131801 (2008)."},{"key":"BFnrneurol20111_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1212\/WNL.53.4.751","volume":"53","author":"A Paolillo","year":"1999","unstructured":"Paolillo, A.  et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53, 751\u2013757 (1999).","journal-title":"Neurology"},{"key":"BFnrneurol20111_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(94)91339-0","volume":"344","author":"T Moreau","year":"1994","unstructured":"Moreau, T.  et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344, 298\u2013301 (1994).","journal-title":"Lancet"},{"key":"BFnrneurol20111_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00228-009-0739-z","volume":"66","author":"C Piccinni","year":"2010","unstructured":"Piccinni, C.  et al. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur. J. Clin. Pharmacol. 66, 199\u2013206 (2010).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"BFnrneurol20111_CR15","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1001\/archneur.63.10.1475","volume":"63","author":"JA Allen","year":"2006","unstructured":"Allen, J. A., Adlakha, A. & Bergethon, P. R. Reversible posterior leukoencephalopathy syndrome after bevacizumab\/FOLFIRI regimen for metastatic colon cancer. Arch. Neurol. 63, 1475\u20131478 (2006).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol20111_CR16","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1056\/NEJMc052954","volume":"354","author":"P Glusker","year":"2006","unstructured":"Glusker, P., Recht, L. & Lane, B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med. 354, 980\u2013981 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol20111_CR17","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","volume":"47","author":"BW van Oosten","year":"1996","unstructured":"van Oosten, B. W.  et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47, 1531\u20131534 (1996).","journal-title":"Neurology"},{"key":"BFnrneurol20111_CR18","doi-asserted-by":"crossref","unstructured":"[No authors listed] TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group. Neurology 53, 457\u2013465 (1999).","DOI":"10.1212\/WNL.53.3.457"},{"key":"BFnrneurol20111_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jns.2006.01.012","volume":"244","author":"JH Chung","year":"2006","unstructured":"Chung, J. H.  et al. Adalimumab-associated optic neuritis. J. Neurol. Sci. 244, 133\u2013136 (2006).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol20111_CR20","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/ard.2009.111500","volume":"69","author":"S Bernatsky","year":"2010","unstructured":"Bernatsky, S., Renoux, C. & Suissa, S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann. Rheum. Dis. 69, 1691\u20131693 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneurol20111_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/mus.20924","volume":"37","author":"JP St\u00fcbgen","year":"2008","unstructured":"St\u00fcbgen, J. P. Tumor necrosis factor-\u03b1 antagonists and neuropathy. Muscle Nerve 37, 281\u2013292 (2008).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol20111_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G. & Tak, P. P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244\u2013279 (2008).","journal-title":"Pharmacol. Ther."},{"key":"BFnrneurol20111_CR23","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/art.21814","volume":"54","author":"IS Shin","year":"2006","unstructured":"Shin, I. S., Baer, A., Kwon, H., Papadopoulos, E. & Siegel, J. Guillain\u2013Barr\u00e9 and Miller Fisher syndromes occurring with tumor necrosis factor \u03b1 antagonist therapy. Arthritis Rheum. 54, 1429\u20131434 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol20111_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/archneurol.2009.11","volume":"66","author":"P Lozeron","year":"2009","unstructured":"Lozeron, P., Denier, C., Lacroix, C. & Adams, D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-\u03b1-blocker therapy. Arch. Neurol. 66, 490\u2013497 (2009).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol20111_CR25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/mus.21584","volume":"41","author":"A Alshekhlee","year":"2010","unstructured":"Alshekhlee, A., Basiri, K., Miles, J. D., Ahmad, S. A. & Katirji, B. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-\u03b1 antagonists. Muscle Nerve 41, 723\u2013727 (2010).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol20111_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10067-006-0436-6","volume":"26","author":"J Birnbaum","year":"2007","unstructured":"Birnbaum, J. Infliximab associated neuropathy in RA patients\u2014the importance of considering the diagnosis of mononeuritis multiplex. Clin. Rheumatol. 26, 281\u2013282 (2007).","journal-title":"Clin. Rheumatol."},{"key":"BFnrneurol20111_CR27","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1212\/01.WNL.0000142974.81103.95","volume":"63","author":"OC Singer","year":"2004","unstructured":"Singer, O. C., Otto, B., Steinmetz, H. & Ziemann, U. Acute neuropathy with multiple conduction blocks after TNF\u03b1 monoclonal antibody therapy. Neurology 63, 1754 (2004).","journal-title":"Neurology"},{"key":"BFnrneurol20111_CR28","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/brain\/awh429","volume":"128","author":"FA Gondim","year":"2005","unstructured":"Gondim, F. A., Brannagan, T. H. 3rd, Sander, H. W., Chin, R. I. & Latov, N. Peripheral neuropathy in patients with inflammatory bowel disease. Brain 128, 867\u2013879 (2005).","journal-title":"Brain"},{"key":"BFnrneurol20111_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/1529-0131(200002)43:2<243::AID-ANR2>3.0.CO;2-K","volume":"43","author":"FW Miller","year":"2000","unstructured":"Miller, F. W.  et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum. 43, 243\u2013249 (2000).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol20111_CR30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s10067-006-0317-z","volume":"26","author":"MG Tektonidou","year":"2007","unstructured":"Tektonidou, M. G., Serelis, J. & Skopouli, F. M. Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. Clin. Rheumatol. 26, 258\u2013260 (2007).","journal-title":"Clin. Rheumatol."},{"key":"BFnrneurol20111_CR31","first-page":"2287","volume":"30","author":"SJ Jarrett","year":"2003","unstructured":"Jarrett, S. J.  et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J. Rheumatol. 30, 2287\u20132291 (2003).","journal-title":"J. Rheumatol."},{"key":"BFnrneurol20111_CR32","first-page":"2079","volume":"31","author":"P Richette","year":"2004","unstructured":"Richette, P.  et al. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J. Rheumatol. 31, 2079\u20132081 (2004).","journal-title":"J. Rheumatol."},{"key":"BFnrneurol20111_CR33","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1002\/art.10488","volume":"46","author":"M Cisternas","year":"2002","unstructured":"Cisternas, M., Guti\u00e9rrez, M. & Jacobelli, S. Successful rechallenge with anti-tumor necrosis factor \u03b1 for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment. Arthritis Rheum. 46, 3107\u20133108 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol20111_CR34","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1212\/01.WNL.0000158681.29117.8B","volume":"64","author":"C Richez","year":"2005","unstructured":"Richez, C. Blanco, P., Lagueny, A., Schaeverbeke, T. & Dehais, J. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-\u03b1 blockers. Neurology 64, 1468\u20131470 (2005).","journal-title":"Neurology"},{"key":"BFnrneurol20111_CR35","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/mus.21051","volume":"38","author":"DR Hooper","year":"2008","unstructured":"Hooper, D. R., Tarnopolsky, M. A. & Baker, S. K. Lewis\u2013Sumner syndrome associated with infliximab therapy in rheumatoid arthritis. Muscle Nerve 38, 1318\u20131325 (2008).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol20111_CR36","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","volume":"361","author":"Y Chen","year":"2009","unstructured":"Chen, Y.  et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N. Engl. J. Med. 361, 1067\u20131074 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol20111_CR37","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1056\/NEJMp0906248","volume":"361","author":"EO Major","year":"2009","unstructured":"Major, E. O. Reemergence of PML in natalizumab-treated patients\u2014new cases, same concerns. N. Engl. J. Med. 361, 1041\u20131043 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol20111_CR38","unstructured":"Xu, L.  et al. The polymorphisms of the TNF-\u03b1 gene in multiple sclerosis?\u2014a meta-analysis. Mol. Biol. Rep. doi: 10.1007\/s11033-010-053320130."},{"key":"BFnrneurol20111_CR39","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0002-9440(10)65395-3","volume":"154","author":"R Bachmann","year":"1999","unstructured":"Bachmann, R., Eugster, H. P., Frei, K., Fontana, A. & Lassmann, H. Impairment of TNF-receptor-1 signaling but not Fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice. Am. J. Pathol. 154, 1417\u20131422 (1999).","journal-title":"Am. J. Pathol."},{"key":"BFnrneurol20111_CR40","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","volume":"361","author":"W Wenning","year":"2009","unstructured":"Wenning, W.  et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N. Engl. J. Med. 361, 1075\u20131080 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol20111_CR41","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/ard.2005.043166","volume":"65","author":"MH Schiff","year":"2006","unstructured":"Schiff, M. H.  et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis. 65, 889\u2013894 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneurol20111_CR42","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/ard.2006.066761","volume":"66","author":"GR Burmester","year":"2007","unstructured":"Burmester, G. R.  et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann. Rheum. Dis. 66, 732\u2013739 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneurol20111_CR43","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/ibd.20956","volume":"15","author":"JF Colombel","year":"2009","unstructured":"Colombel, J. F.  et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis. 15, 1308\u20131319 (2009).","journal-title":"Inflamm. Bowel Dis."},{"issue":"Suppl. 35","key":"BFnrneurol20111_CR44","first-page":"S134","volume":"22","author":"MD Magnano","year":"2004","unstructured":"Magnano, M. D., Robinson, W. H. & Genovese, M. C. Demyelination and inhibition of tumor necrosis factor (TNF). Clin. Exp. Rheumatol. 22 (Suppl. 35), S134\u2013S140 (2004).","journal-title":"Clin. Exp. Rheumatol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2011.1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2011.1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2011.1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:59:30Z","timestamp":1684472370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2011.1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,25]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["BFnrneurol20111"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2011.1","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,25]]}}}